Treatment of extraintestinal complications of ulcerative colitis

European Journal of Gastroenterology and Hepatology

Volumn 9, Issue 9, 1997, Pages 850-853

  Lamers, Cornelis B H W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arthritis; Erythema nodosum; Extraintestinal disease; Liver transplantation; Primary sclerosing cholangitis; Pyoderma gangrenosum; Ulcerative colitis; Uveitis

Indexed keywords

ARTHRITIS; DISEASE COURSE; DISEASE SEVERITY; ERYTHEMA NODOSUM; HUMAN; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTOCOLECTOMY; PYODERMA GANGRENOSUM; SHORT SURVEY; ULCERATIVE COLITIS; UVEITIS;

EID: 0030772568     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199709000-00005     Document Type: Short Survey

References (18)

1. Danzi JT: Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch Intern Med 1988, 148:297-302. Comprehensive overview of extraintestinal manifestations of inflammatory bowel disease.
2. Weiss A, Mayer L: Extraintestinal manifestations of inflammatory bowel disease. In Inflammatory Bowel Disease. Edited by Allan RN, Rhodes JM, Hanauer SB, et al. New York: Churchill Livingstone; 1997:623-632. Excellent chapter in an excellent textbook.
3. Hossein Mir-Madjlessi S, Taylor JS, Farmer RC: Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 1985, 80:615-620. Clinical experiences of 42 ulcerative colitis patients with erythema nodosum or pyoderma gangrenosum in a large referral clinic in the USA.
4. Levitt MD, Ritchie JK, Lennard-Jones JE, et al.: Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991, 78: 676-678. Clinical experiences of 34 patients with inflammatory bowel disease complicated by pyoderma gangrenosum in a large referral centre in the UK.
5. Shelley ED, Shelley WB: Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis. J Am Acad Dermatol 1988, 18:1084-1088. Case history of a patient with pyoderma gangrenosum, resistant to conventional therapies, responding to cyclosporin. This response was associated with a remission of colitis and sclerosing cholangitis.
6. Saffouri B, Hom BM, Mertesdorf JM, et al.: Treatment of pyoderma gangrenosum with disodium cromoglycate. Dig Dis Sci 1984, 29:183-185. Case of pyoderma gangrenosum responding to topical disodium cromoglycate therapy.
7. Kaplan B, Trau H: Treatment of pyoderma gangrenosum with clofazimine. Int J Dermatol 1992, 31:591-393. Case of pyoderma gangrenosum responding to clofazimine, an antimicrobial agent used in the therapy of infections with Mycobacterium leprae.
8. Galun E, Flugelman MY, Rachmilewitz D: Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 1986, 81:988-989. Case of pyoderma gangrenosum responding to methylprednisolone and dapsone, a sulphonamide used in the therapy of leprosy and dermatitis herpetiformis.
9. Cave DR, Burakoff R: Pyoderma gangrenosum associated with ulcerative colitis: treatment with disodium cromoglycate. Am J Gastroenterol 1987, 82:802-804. Two cases with pyoderma gangrenosum associated with ulcerative colitis successfully treated with topical disodium cromoglycate therapy.
10. Soukiasian S, Foster CS, Raizman MB: Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 1994, 118:601-611. Experiences with the therapy of scleritis and uveitis in 19 patients with inflammatory bowel disease in a single centre in the USA.
11. Cravallese EM, Kantrowitz FC: Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988, 83:703-709. Comprehensive overview of rheumatological conditions associated with inflammatory bowel disease.
12. Wiesner RH: Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994, 69:969-982. Review of epidemiology, aetiopathogenesis, natural history, and therapy of primary sclerosing cholangitis.
13. Kaplan MM: Toward better treatment of primary sclerosing cholangitis. N Engl J Med 1977, 336:719-721. Editorial in relation to reference 14, discussing the finding of the lack of benefit of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Suggestions for further therapeutic approaches are given.
14. Lindor KD: Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997, 336:691-695. Well-performed placebo-controlled study failing to show clinical benefit of ursodeoxycholic acid in primary sclerosing cholangitis.
15. Kaplan MM, Arora S, Pincus SH: Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Ann Intern Med 1987, 106:231-235. Report of two cases of primary sclerosing cholangitis responding to oral pulse therapy with a low dose of methotrexate.
16. Sandborn WJ, Wiesner RH, Tremaine WJ, et al.: Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1992, 34:242-246. This study suggests that immunosuppressive therapy with cyclosporin therapy is beneficial in patients with ulcerative colitis associated with primary sclerosing cholangitis.
17. Stiehl A, Walker S, Stiehl L, et al.: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57-64. The results of this study show that therapy of primary sclerosing cholangitis with ursodeoxycholic acid is promising but that further evaluation is necessary.
18. Rubin RA, Kowalski TE, Khandelwal M, et al.: Ursodiol for hepatobiliary disorders. Ann Intern Med 1994, 121:207-218. Review of therapeutic trials of ursodeoxycholic acid in patients with cholesterol gallstones and chronic liver diseases, including primary sclerosing cholangitis.